Related Experiment Video

Updated: Jun 15, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Pharmacogenetics in treatment of rheumatoid arthritis

W M Kooloos1, T W J Huizinga, H-J Guchelaar

  • 1Dept. of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Current Pharmaceutical Design
|March 9, 2010
PubMed

Insights

Pharmacogenetics shows promise for personalizing rheumatoid arthritis (RA) treatment by identifying drug response markers. However, current evidence requires further validation before clinical use in guiding RA therapy.

Area of Science:

  • Rheumatology
  • Pharmacogenetics
  • Immunology

Background:

  • Disease-modifying anti-rheumatic drugs (DMARDs) have advanced rheumatoid arthritis (RA) treatment.
  • Many patients show poor response or toxicity to DMARDs, leading to disease progression.
  • Interindividual variability in drug response necessitates prognostic markers for personalized RA therapy.

Purpose of the Study:

  • To review the current state of pharmacogenetic markers for predicting drug response in RA.
  • To assess the feasibility of clinical implementation of pharmacogenetics in RA treatment.

Main Methods:

  • Review of existing literature on pharmacogenetic studies in RA patients.
  • Analysis of reported genetic markers associated with response to methotrexate and TNF inhibitors.
  • Evaluation of the reliability and interpretation of current pharmacogenetic findings.

Main Results:

  • Pharmacogenetic studies have identified potential markers for RA drug response.
  • Conflicting results and interpretation challenges limit definitive conclusions.
  • Clinical implementation of pharmacogenetics for RA is not yet feasible due to insufficient evidence.

Conclusions:

  • Pharmacogenetics holds potential for individualizing RA drug therapy.
  • Replication and prospective validation in large cohorts are essential.
  • Genotyping RA patients requires further research before guiding clinical decisions.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...